Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab for Acquired Angioedema Prophylaxis
NCT06818474Phase 4Recruiting
- Sponsor
- Bernstein Allergy Group and Clinical Research Center
- Start
- Jun 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of lanadelumab in acquired angioedema (AAE), sponsored by Bernstein Allergy Group and Clinical Research Center. Started Jun 2024; status: recruiting.
02
Drugs
lanadelumab
03
Conditions
acquired angioedema (AAE)
Beyond the preview
Go deeper on NCT06818474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06818474.